Why sponsors are looking at Asia Pacific for biologics outsourcing

Sponsors are evaluating CDMO companies in Asia Pacific because the region now holds inspected capacity and regulators that take part in the same harmonization schemes as FDA and EMA. Regulators in Taiwan, Japan, Korea and Singapore joined PIC/S, single-use 2,000 L trains lowered the capital needed for antibody capacity, and biosimilar programs created regional facilities that have been through FDA, EMA and PMDA review.

The result is wider choice and wider variance in quality. What separates the top CDMO companies in Asia Pacific from the rest is not price. It is the depth of the inspection record, the realism of the scale path, and the contract terms that apply when something goes wrong. The six criteria below let a sponsor score any candidate from documents and one site visit.

Criterion 1: regulatory track record (FDA, PMDA, PIC/S, EMA)

A regulatory track record is the most reliable discriminator among CDMO companies in Asia Pacific, because it is externally verified. Score it in three layers.

Home-regulator GMP status under PIC/S. PIC/S membership means the inspectorate applies the PIC/S GMP guide and is peer-assessed. Taiwan's TFDA joined in 2013, Japan's PMDA/MHLW and Korea's MFDS in 2014; Singapore's HSA and Australia's TGA are long-standing members.

Foreign-regulator approvals tied to a marketed product. An FDA pre-license or pre-approval inspection with an acceptable outcome, a PMDA foreign manufacturer accreditation, or an EU GMP certificate after an EMA-coordinated inspection each show that the facility supported a filing. Ask for inspection dates, the product, and whether the outcome was No Action Indicated or Voluntary Action Indicated. An Official Action Indicated outcome, warning letter or EU non-compliance statement is disqualifying unless remediated.

Depth of history. Count the years between first certification and the latest inspection, and ask how many inspections of each type have occurred. The top CDMO companies in Asia Pacific can produce this list on request.

Criterion 2: capacity and scale path

Capacity should be scored as a path from the sponsor's current scale to launch volume, not as a headline number of liters. A site with 2,000 L production but no 50 L or 200 L step forces a scale jump; one that stops at 500 L forces a second transfer before launch.

Check four things. The equipment ladder: bench, pilot single-use and production vessels on the same host and media platform. Bioreactor technology: stainless steel gives lower consumable cost at high volume; single-use gives faster changeover and lower cross-contamination risk for multi-product sites. Downstream fit: column diameters and ultrafiltration areas must match the upstream titer at each scale, or the bottleneck moves. Slot availability: ask for booked occupancy over the next 24 months and how a delayed clinical readout is handled. Annual output in kilograms of antibody is a useful check if the titer and batch assumptions are disclosed.

Criterion 3: modality coverage (mAb, bispecific, ADC, microbial)

Modality coverage matters because a pipeline rarely stays within one format, and moving a second molecule to a second CDMO repeats every qualification cost. Score it against what the sponsor will need within five years.

• Monoclonal antibodies. The baseline: CHO platform experience, Protein A capture at scale and a validated viral clearance package.
• Bispecific and multispecific antibodies. Ask which formats have been made, how mispaired species are removed, and whether icIEF, CE-SDS and mass spectrometry are run in-house.
• Antibody-drug conjugates. Conjugation needs high-potency containment, a payload and linker supply chain, and drug-to-antibody ratio analytics. Few CDMO companies in Asia Pacific offer antibody production and conjugation under one quality system; those that do remove a vendor boundary.
• Microbial products. E. coli and Pichia pastoris processes need fermentation, homogenization and refolding capability that mammalian-only sites lack.

Criterion 4: cost structure and currency

Cost should be compared on total program cost and quote structure, not per-batch price. A low batch price with high charges for development, testing and change orders often costs more than a higher batch price that bundles them.

Ask for the quote in a fixed structure: development by phase, per-batch manufacturing, testing per lot, regulatory support, and the unit price of a change order. Ask which costs are pass-through, how failed batches are charged, and how the liability cap compares with batch value.

Over a multi-year program, currency is a real risk. Most CDMO companies in Asia Pacific quote in US dollars but incur costs in local currency, so exchange movements surface as price revisions or margin pressure. Agree which party carries that risk, how long prices are fixed, and what triggers a renegotiation.

Criterion 5: IP protection and contract terms

IP protection depends more on the contract and the CDMO's practices than on the country, provided trade-secret law is enforced. Taiwan, Japan and Korea have trade-secret statutes with criminal penalties.

In the master services agreement, check six clauses: ownership of sponsor background IP and of process improvements made with sponsor material; the CDMO's platform IP and the sponsor's license to use it after transfer; confidentiality that survives termination and binds sub-contractors; data ownership and the right to receive batch records, development reports and raw data; transfer-out obligations and fees; and governing law and dispute resolution.

Ask also whether the CDMO makes its own products in the same facility. A biologics CDMO that develops biosimilars should show the firewall between its product unit and client programs in the quality agreement.

Criterion 6: supply-chain resilience and geography

Resilience is scored by asking what happens when one site, one supplier or one shipping lane fails. The answers differ by geography.

Sites. Two sites in different locations allow a second-site contingency; a single site needs a business-continuity plan naming an alternative. Ask where the master cell bank is stored and whether an off-site backup exists.

Natural hazards and utilities. Typhoon, earthquake and flood exposure vary across the region. Ask for the site risk assessment, backup power in hours, and water-for-injection redundancy.

Raw materials. Media, resins, single-use assemblies and filters are mostly imported. Ask about inventory policy for critical consumables, validated dual sourcing, and lead times during recent disruptions. Confirm cold-chain routes to the fill-finish site.

Scorecard and red flags

Scoring the six criteria on a 1-to-5 scale, weighted to the program, turns a long list of CDMO companies in Asia Pacific into a defensible shortlist. The table gives the evidence to request and the red flag that removes a candidate.

A site visit is the final filter. Spend it in the QC laboratory and the deviation system rather than the bioreactor hall, because the top CDMO companies in Asia Pacific are distinguished by how they investigate problems. Awards prompt questions; they do not replace the scorecard.